Delix Therapeutics is a clinical-stage neuroscience company focused on harnessing the power of novel neuroplasticity'promoting therapeutics to better treat patients struggling with difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Through its novel Neuroplastogen Platform, Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and rapidly advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that are intended to serve several unmet needs and enhance the psychiatric treatment paradigm for patients and providers.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/09/26	$100,000,000	Series C	Adage Capital Management Artis Ventures Bail Capital Dementia Discovery Fund Dolby Family Ventures Hamilton Square Partners Management Johnson & Johnson Innovation OMX Ventures RA Capital SV Health Investors UC Investments Vestal Point Capital YK Bioventures	undisclosed